BioLineRx (BLRX) Assets Average (2011 - 2025)

BioLineRx's Assets Average history runs 15 years deep, the most recent figure standing at $40.4 million for Q4 2025.

• On a quarterly basis, Assets Average fell 11.94% year-over-year to $40.4 million in Q4 2025; TTM through Dec 2025 was $40.4 million, a 11.94% decrease from a year earlier, with the FY2025 full-year figure at $39.9 million, down 22.39% from the prior year.
• Assets Average slipped to $40.4 million in Q4 2025 per BLRX's latest filing, from $41.5 million in the prior quarter.
• Across five years, Assets Average topped out at $89.1 million in Q3 2021 and bottomed at $40.4 million in Q4 2025.
• The 5-year median for Assets Average is $61.2 million (2023), against an average of $63.3 million.
• Across the five-year window, Assets Average soared 80.33% in 2021 and slipped 29.2% in 2025, its largest moves.
• Year by year, Assets Average stood at $84.1 million in 2021, then decreased by 6.08% to $79.0 million in 2022, then declined by 26.12% to $58.4 million in 2023, then dropped by 21.52% to $45.8 million in 2024, then declined by 11.94% to $40.4 million in 2025.
• Per Business Quant, the three latest BLRX Assets Average figures stand at $40.4 million (Q4 2025), $41.5 million (Q3 2025), and $43.4 million (Q2 2025).